M&A Path Widens For Chinese Drug Companies With R&D Foundations
This article was originally published in PharmAsia News
Executive Summary
Chinese drug companies are benefitting from government policies that stress R&D, with many now in play as they build up expertise in therapeutic areas in hot demand, according to an analysis.